Barclays
PRCT icon

Barclays’s Procept Biorobotics PRCT Stock Holding History

Barclays’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,000
Closed -$2.48M – 5434
2024
Q3 		$2.48M Buy
+31,000
New +$2.2M ﹤0.01% 2677

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barclays's PRCT Position: Q1 2026 in Review

Barclays increased its Procept Biorobotics (PRCT) stake by 38% in Q1 2026, buying an estimated $1.02M and bringing the position to 132,487 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Barclays first reported a position in PRCT in Q1 2022 and has held it in 17 quarters since. The position peaked at $12.6M in Q4 2024. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Barclays held 132,487 shares of Procept Biorobotics worth $3.31M as of Q1 2026.
  • Barclays bought 36,158 Procept Biorobotics shares in Q1 2026, an estimated $1.02M.
  • Procept Biorobotics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2063 holding.
  • Barclays first reported a position in Procept Biorobotics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Procept Biorobotics position peaked at $12.6M in Q4 2024.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.